



## Quick Facts

Website: [www.organovo.com](http://www.organovo.com)

Headquarters: San Diego, CA, USA

Founded: 2007

Employees: 100+ globally

Fiscal 2015 Revenue: \$0.6 million

## Stock Information

Ticker Symbol: ONVO

Stock Exchange: NYSE MKT (Listed 2013)

Shares Outstanding: 92.3 million

Insider Ownership: 12%

Investor Relations: [ir@organovo.com](mailto:ir@organovo.com)

## Management Team

### Keith Murphy

Chairman and Chief Executive Officer

### Sharon Collins Presnell, Ph.D.

Chief Technology Officer and  
EVP, Research and Development

### Susan Daugherty

Vice President, Human Resources

### Eric Michael David, M.D., J.D.

Chief Strategy Officer and  
EVP, Preclinical Development

### Paul Gallant

General Manager, In Vitro Tissue Services  
and Products

### Jennifer Kinsbruner Bush, J.D.

General Counsel and Corporate Secretary

### Barry Michaels

Chief Financial Officer

## About Organovo


Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. We develop 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Our 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In November 2014, we launched the initial product of the planned exVive3D™ portfolio offering, the exVive3D Human Liver Tissue for use in toxicology and other preclinical drug testing. We also actively conduct research on specific tissues for therapeutic use in direct surgical applications.

## Our Vision and Business

**We're changing the shape of medical research and practice.** Our goal is to address the gaps that exist in pharmaceutical discovery and significantly impact the cost, predictability and speed of drug development. We provide superior predictive solutions that recreate 3D native tissue architecture, which allows our customers to de-risk their drug discovery programs by enabling decisions points further upstream. We also have the potential to revolutionize therapeutic applications by creating tissue replacement products for surgical implantation, addressing the dramatic supply issues that are a constant challenge in transplant medicine.

## Investment Highlights

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong intellectual property (IP) portfolio
- We expect to grow revenue by building a robust product and service platform



© 2015 Organovo Holdings, Inc. All rights reserved. Current as of 31 October 2015

*Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the market acceptance of the Company's products and services; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings. These and other factors are identified and described in more detail in the Company's filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.*